Over the past few years, remarkable advances have been made in treatments for previously incurable diseases. Most relevant to me is the approval of lecanemab for use in the UK and elsewhere to slow the progression of early Alzheimer’s disease. This is not a cure, but it brings dementia closer to becoming a chronic disease that can be managed with drugs.
But while recanemab has been hailed as a game-changer, it is still not readily available, and in the meantime, 55 million people worldwide are living with dementia. By 2050, that will increase to 139 million people. It is one of the biggest medical…
